Legal notice
Thank you for your interest in this part of the website of Takeda Pharmaceutical Company Ltd. (“Takeda”).
IMPORTANT: Please read this notice carefully – it applies to all persons who view the site and, depending on who you are and where you live, it may affect your rights. You should read it in full each time you visit the site. Viewing parts of the site may not be lawful in certain jurisdictions.
Takeda is pleased to provide HCPs outside the US and UK treating patients with hyperparathyroidism with this website and its content for general informational purposes. Please carefully read these terms and conditions relating to the use of our website. Takeda will use its best efforts to ensure that the information is accurate at the time it is added to the website.
Please note, however, that Takeda cannot guarantee that the information is accurate and accepts no liability for any losses or damage that may arise from relying on this information. The information may be changed by Takeda at any time, without notice to you. By using this website, you agree to these terms and conditions without limitation or qualification.
Use of materials and intellectual property rights
The copyright in this website belongs to Takeda. All other intellectual property rights are reserved. Takeda authorizes you to copy materials published on this website for non-commercial use only, provided that any copy of these materials which you make retains all copyright and other proprietary notices.
Links to third party websites
The website may from time to time contain hypertext-links to third parties’ websites. Takeda is not responsible for, and accepts no liability in respect of, any information or opinion contained on any other such site. As Takeda has no control over such sites and because their content is subject to change without notice to Takeda it is the responsibility of the user of the site to ensure that any information accessed is accurate and that software which is downloaded from that site is free of viruses or any other items of a destructive nature. Takeda and its subsidiaries accept no liability whatsoever in respect of any loss, damage, costs or liability incurred through any such downloaded material.
No Representation or Warranty
Takeda is not responsible for computer damage resulting from using the website. Takeda makes no representation or warranty that access to the website will be available on a timely basis, will be uninterrupted, or will be error-free. Takeda does not warrant that these pages, or the server that makes them available, are free of viruses or other harmful elements. In no event shall Takeda, its affiliates and subsidiaries, and their respective officers, directors, employees, agents, representatives, information providers, and licensors and their respective heirs and assigns, be liable for any direct, indirect, incidental, consequential, exemplary, special, punitive, or other damages even if informed of the possibility of such damages. The above exclusion may not apply in jurisdictions to the extent that they do not allow the exclusion of implied warranties.
Information
Any personally identifiable information in electronic communications to this website is governed by Takeda’s privacy policy.
Natpar® (parathyroid hormone (rDNA)
Detailed Safety Information
Please consult the Natpar Summary Product Characteristics (SmPC) before prescribing.
Natpar treatment should be supervised by a physician or other qualified healthcare professional experienced in the management of patients with hypoparathyroidism. The goal of treatment is to achieve calcaemic control and to reduce symptoms. The optimisation of parameters of calcium phosphate metabolism should be in line with current therapeutic guidelines for the treatment of hypoparathyroidism. Prior to initiating and during treatment with Natpar confirm that 25-OH vitamin D stores are sufficient and that serum magnesium is within the reference range.
Contraindications
Natpar is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients, who are receiving or who have previously received radiation therapy to the skeleton, with skeletal malignancies or bone metastases, who are at increased baseline risk for osteosarcoma, with unexplained elevations of bone-specific alkaline phosphatase, with pseudohypoparathyroidism.
Warnings and Precautions
Monitoring of patients during treatment: pre-dose and in some cases post-dose serum calcium levels must be monitored during treatment with Natpar.
Hypercalcaemia: this was reported in clinical trials with Natpar. Hypercalcaemia commonly occurred during the titration period, during which doses of oral calcium, active vitamin D, and Natpar were being adjusted. Hypercalcaemia may be minimized by following the recommended dosing, the monitoring information and asking patients about any symptoms of hypercalcaemia. If severe hypercalcaemia develops, hydration and temporarily stopping Natpar, calcium and active vitamin D should be considered until serum calcium returns to the normal range. Then consider resuming Natpar, calcium and active vitamin D at lower doses.
Hypocalcaemia: a common clinical manifestation of hypoparathyroidism was reported in clinical trials with Natpar. Most of the hypocalcaemic events occurring in the clinical trials were mild to moderate severity. The risk for serious hypocalcaemia was greatest after the withdrawal of Natpar. Temporary or permanent discontinuation of Natpar must be accompanied by monitoring of serum calcium levels and increase of exogenous calcium and/or vitamin D sources as necessary. Hypocalcaemia may be minimized by following the recommended dosing, the monitoring information, and asking patients about any symptoms of hypocalcaemia.
Concomitant use with cardiac glycosides: Hypercalcaemia of any cause may predispose to digitalis toxicity, monitor serum calcium and cardiac glycoside levels and patients for signs and symptoms of digitalis toxicity.
Severe renal or hepatic disease: Natpar should be used with caution in patients with severe renal or hepatic disease because they have not been evaluated in clinical trials.
Use in young adults: Natpar should be used with caution in young adult patients with open epiphyses.
Tachyphylaxis: the calcium-raising effect of Natpar may diminish over time in some patients. The response of serum calcium concentration to administration of Natpar should be monitored at intervals to detect this and the diagnosis of tachyphylaxis considered.
Urolithiasis: Natpar has not been studied in patients with urolithiasis. Natpar should be used with caution in patients with active or recent urolithiasis because of the potential to exacerbate this condition.
Adverse Reactions
The most commonly observed adverse events with Natpar treatment were hypercalcaemia, hypocalcaemia, headache, diarrhoea, vomiting, paraesthesia, hypoaesthesia and hypercalciuria.
|
Very common
(frequency ≥1/10): |
Hypercalcaemia, hypocalcaemia, headache, hypoaesthesia, paraesthesia, diarrhoea, nausea, vomiting, arthralgia, and muscle spasms. |
|
Common
(≥1/100 to <1/10): |
Hypomagnesaemia, tetany, anxiety, insomnia, somnolence, palpitations, hypertension, cough, upper abdominal pain, muscle twitching, musculoskeletal pain, myalgia, neck pain, pain in extremities, hypercalciuria, pollakiuria, asthenia, chest pain, fatigue, injection site reactions, thirst, anti-PTH antibody positive, blood 25-hydroxycholecalciferol decreased, vitamin D decreased. |
Material code: pi-00658
Date of Preparation of SI: February 2019
Prescribing Information
| Body weight (kg) | Volume to be injected (mL) |
|---|---|
| 38–41 | 0.xx |
| 42–45 | 0.xx |
| 46–49 | 0.xx |
| 50–53 | 0.xx |
| 54–57 | 0.xx |
| 58–61 | 0.xx |
| 62–65 | 0.xx |
| 66–69 | 0.xx |
| 70–73 | 0.xx |
| 74–77 | 0.xx |
| 78–81 | 0.xx |
| 82–85 | 0.xx |
| 86–89 | 0.xx |
| 90–93 | 0.xx |